Eli Lilly (LLY) News
NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1,179.27+9.67 (+0.83%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
LLY news summary
We found 50 recent headlines mentioning Eli Lilly (LLY): 42 in the past week and 50 in the past 30 days, most often from Nasdaq, Seeking Alpha, PR Newswire. For price context, LLY is up 0.83% at $1,179.27. The most recent story, "Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Eli Lilly headlines
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) - This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.NasdaqABBV, ALVO, ARGX, BBIO
- Lilly Study Shows Broader Biomarker Changes With Taltz-Zepbound Combination In Psoriasis(RTTNews) - Eli Lilly and Company (LLY) presented new exploratory data from its Phase 3b TOGETHER-PsO trial, providing additional insight into the biological psoriasis and obesity and the potential…Nasdaq
- Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending StockLilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Nasdaq
- Why Investors Need to Take Advantage of These 2 Medical Stocks NowInvestors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.NasdaqUTHR, LLY
- Eli Lilly: Weight-Loss Money Machine Isn't Slowing DownSeeking Alpha
- Lilly Highlights Immune And Metabolic Effects Of Taltz Plus Zepbound(RTTNews) - Friday, Eli Lilly (LLY) reported new exploratory Phase 3b data from the TOGETHER-PsO study evaluating Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with psoriasis and obesity or…Nasdaq
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesityExploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS,…PR Newswire
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.Key PointsUBS analyst Michael Yee believes investors prefer Eli Lilly's growth story to Novo Nordisk's turnaround story.NasdaqNVO, LLY
- 2 Growth Stocks to Buy in OctoberKey PointsGrail’s stock could skyrocket if the FDA approves Galleri.NasdaqMRK, LLY, PFE, VEEV
- Top Analyst Reports for Eli Lilly, Procter & Gamble & ShellEli Lilly's GLP-1 momentum, new drugs and M&A deals support growth, while pricing pressure and competition pose headwinds.NasdaqPG, LLY, AERT, PNRG
- Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare PlatformEli Lilly (NYSE: LLY) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and…Nasdaq
- Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next.Key PointsPfizer has existed for more than 100 years.NasdaqPFE, LLY
- Eli Lilly (LLY) Just Overtook the 50-Day Moving AverageWhen a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?Nasdaq
- LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?LLY's recent dip reflects valuation and competition concerns, but strong GLP-1 demand, pipeline growth and diversification support its long-term outlook.NasdaqLLY, NVO, VKTX, GPCR
- If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth NowWhy investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.Nasdaq
- How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.NasdaqLLY, AZN, PFE, MRK
- Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A PremiumSeeking Alpha
- Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond ZepboundKey PointsEli Lilly has attractive pipeline candidates within its core therapeutic area.NasdaqLLY, NVO, AMGN
- Pharma lobby group sues Trump administration over MFN pricingSeeking Alpha
- VKTX Advances Obesity Program With New Oral Maintenance StudyVK2735's oral maintenance study could expand Viking Therapeutics' obesity strategy by helping sustain weight loss with less frequent dosing.NasdaqVKTX, NVO, LLY
- Eli Lilly: Losing Weight, Gaining ExpectationsSeeking Alpha
- Eli Lilly: Buy The GLP-1 Growth PremiumSeeking Alpha
- Can Redwire's Microgravity Pharma Work Create New Revenue Streams?RDW expands microgravity applications into pharmaceutical research, creating potential revenue streams through research and licensing.NasdaqRDW, BMY, LLY
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.NasdaqNVO, LLY, ALT, MDGL
- Eli Lilly: Dominance Has A PriceSeeking Alpha
- Eli Lilly: Quiet Momentum Builds Into Q3 Earnings, But Watch The Chart TooSeeking Alpha
- The "Trumpflation" Trade Could Get Worse Before It Gets Better. History Says These 2 Stocks Are the Place to Hide.Key PointsThe conflict in the Middle East is driving up energy prices, which impacts costs throughout the economy.NasdaqMDT, LLY
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?Key PointsNovo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug.NasdaqNVO, LLY
- Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should KnowEli Lilly (LLY) closed at $1 in the latest trading session, marking a +1.26% move from the prior day.Nasdaq
- Noteworthy Tuesday Option Activity: PWR, LLY, CIENAmong the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Quanta Services, Inc. (Symbol: PWR), where a total of 6,576 contracts have traded so far,…NasdaqPWR, LLY, CIEN
- Eli Lilly's Breakout May Occur Soon - H2'26 Foundayo TailwindsSeeking Alpha
- Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?Key PointsEli Lilly and shows rapid expansion with metabolic health treatments and high revenue growth.NasdaqLLY, NVO
- VKTX Down 16% in a Month: Time to Invest or Exit the Stock?Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.NasdaqVKTX, NVO, LLY
- Eli Lilly: Impressive Growth, Questionable ValuationSeeking Alpha
- Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its StockKey PointsEli Lilly's stock has soared over the past five years, and its valuation is elevated.Nasdaq
- This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares DoubledKey PointsGinkgo Bioworks and Eli Lilly announced a partnership last month focused on AI drug discovery.NasdaqDNA, LLY
- Pfizer vs. J&J: Comparing Growth, Patent Risks and ValuationJ&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.NasdaqJNJ, PFE, NVO, LLY
- If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It ForeverKey PointsWarren Buffett guided the Berkshire Hathaway investment company to market-beating returns for 60 years.NasdaqVOO, WMT, MSFT, GOOGL
- Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Key PointsEli Lilly's dominance in metabolic health through blockbuster weight-loss drugs.NasdaqLLY, PFE
- FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingLLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.NasdaqLLY, AZN, JNJ, ABBV
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?Key PointsNovo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited.NasdaqPFE, NVO, LLY
- Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.Key PointsEli Lilly is seeing huge demand for its GLP-1 weight-loss drugs and using the cash influx to diversify.NasdaqJNJ, LLY, MDT
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury NoteThe 10-year Treasury note yielded around 5.3% in late September. One month before, it was around 4.78%, and it's up by more than a full percentage point from where it was one year ago. To put that…NasdaqPFE, LLY, ABBV, MRK
- 3 of the Best ETFs to Buy and Hold if a Recession Is ComingKey PointsVHT is a diversified play on the non-cyclical healthcare sector.NasdaqMRK, MSFT, GOOGL, AAPL
- Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinLLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.NasdaqREGN, PFE, NVO, LLY
- ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.NasdaqABBV, JNJ, MRK, LLY
- Eli Lilly and Company (LLY) Presents at 2026 EASD Annual Meeting - SlideshowSeeking Alpha
- 4 Stocks That Could Split Next—and Why Investors Are WatchingStock splits don't change fundamentals or company value; they do a lot for investors, ultimately driving equity gains. At face value, a stock split signals underlying company strength: the stock is…NasdaqAZO, ORLY, LLY, NVO
- Sanofi's New Drugs Poised to Drive Growth Beyond DupixentSNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.NasdaqSNY, REGN, AZN, LLY
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart RingOura Inc. (NASDAQ: OURA) launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept. 28. Offering 50 million shares priced between $40 and $44…NasdaqLLY, DXCM, GRMN